Basal-IQ technology in the real world: satisfaction and reduction of diabetes burden in individuals with type 1 diabetes.

Laurel H MesserK CampbellL PyleG P Forlenza

Published in: Diabetic medicine : a journal of the British Diabetic Association (2020)

The Basal-IQ system increased device satisfaction and reduced diabetes impact in all users in the first 2 months of use, and satisfaction was sustained over 6 months, with small fluctuations.

Keyphrases

type diabetes
cardiovascular disease
glycemic control
risk factors
insulin resistance